Right Ventricular Function in Patients Taking Carfilzomib

Central Hospital, Nancy, France

Status: Completed

Conditions: Pulmonary Hypertension

Study type: Observational

Funder types: Other

Identifiers

NCT06568952

2023PI0512

Details and patient eligibility

About

Patients treated for multiple myeloma in the second line with carfilzomib may develop pulmonary hypertension. This is well documented in the literature. However, there are no studies looking at right ventricular function in these patients, both before and during treatment.

Full description

Patients treated for multiple myeloma in the second line with carfilzomib may develop pulmonary hypertension. This is well documented in the literature. However, there are no studies looking at right ventricular function in these patients, both before and during treatment.

Patients had a cardiac ultrasound scan prior to the introduction of carfilzomib and an ultrasound scan following the introduction of carfilzomib. We will look at the evolution of right ventricular function parameters in these patients.

Enrollment: 36 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients treated for multiple myeloma with carfilzomib
• Patients with echocardiogram before and under treatment.

Exclusion criteria

• /